Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Shares of Danaher Corp. slipped 5.54% to $186.81 Wednesday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index falling 1.61% to 5,844.61 and Dow Jones ...

Danaher Corporation DHR has been benefiting from strength in its bioprocessing business, driven by an increase in demand for consumables from large pharmaceutical customers in North America, Europe ...

DHR and AstraZeneca team up to develop AI-powered diagnostics, aiming to boost precision medicine by improving patient ...

Danaher Corporation (NYSE:DHR) and AstraZeneca PLC (NASDAQ:AZN) have announced a major partnership to accelerate the ...

Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An ...

Explore Third Point’s Q1 2025 portfolio shifts, new investments, stake increases, and high-conviction strategies for ...

Danaher Corp. closed 34.49% below its 52-week high of $281.70, which the company achieved on August 1st.

Danaher Corporation, a key player in Life Sciences, Biotechnology, and Diagnostics, has shown mixed financial performance with recent declines in revenue and net earnings. Despite recent struggles ...

Danaher Corp. engages in the design, manufacture, and marketing of professional, medical, industrial, and commercial products and services. It operates through the following segments ...

Sept 14 (Reuters) - Danaher Corp (DHR.N), opens new tab said on Wednesday it would separate its environmental & applied solutions (EAS) segment to pivot growth towards the medical technology firm ...

Last week, readers were most interested in a story about what's up Roche's sleeve as it talked about its plans during its investor day.